> Detailanzeige

Roehrig, Christian; Huemer, Markus; Lorgé, Dominique; Arn, Fabienne; Heinrich, Nadine; Selvakumar, Lavanja; Gasser, Lynn; Hauswirth, Patrick; Chang, Chun-Chi; Schweizer, Tiziano A.; Eichenseher, Fritz; Lehmann, Steffi; Zinkernagel, Annelies S.; Schmelcher, Mathias

MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections
  • Beteiligte: Roehrig, Christian; Huemer, Markus; Lorgé, Dominique; Arn, Fabienne; Heinrich, Nadine; Selvakumar, Lavanja; Gasser, Lynn; Hauswirth, Patrick; Chang, Chun-Chi; Schweizer, Tiziano A.; Eichenseher, Fritz; Lehmann, Steffi; Zinkernagel, Annelies S.; Schmelcher, Mathias
  • Erschienen: American Society for Microbiology, 2024
  • Erschienen in: mBio, 15 (2024) 2
  • Sprache: Englisch
  • DOI: 10.1128/mbio.02540-23
  • ISSN: 2150-7511
  • Schlagwörter: Virology ; Microbiology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: One of the most pressing challenges of our era is the rising occurrence of bacteria that are resistant to antibiotics. Staphylococci are prominent pathogens in humans, which have developed multiple strategies to evade the effects of antibiotics. Infections caused by these bacteria have resulted in a high burden on the health care system and a significant loss of lives. In this study, we have successfully engineered lytic enzymes that exhibit an extraordinary ability to eradicate staphylococci. Our findings substantiate the importance of meticulous lead candidate selection to identify therapeutically promising peptidoglycan hydrolases with unprecedented activity. Hence, they offer a promising new avenue for treating staphylococcal infections.
  • Zugangsstatus: Freier Zugang